Glucose and cardiovascular risk

Netherlands Journal of Medicine

Volumn 60, Issue 5, 2002, Pages 192-199

  Fuchs, M ^a   Hoekstra, J B L ^b   Mudde, A H ^a  

^a SLINGELAND HOSPITAL   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN;

CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CORRELATION ANALYSIS; DIABETES MELLITUS; DIET RESTRICTION; DISEASE CLASSIFICATION; FREQUENCY ANALYSIS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; MEDICAL RESEARCH; MEDICAL SOCIETY; METABOLIC SYNDROME X; NORMAL VALUE; PROVOCATION TEST; REFERENCE VALUE; REVIEW; STANDARD; WORLD HEALTH ORGANIZATION; CARDIOVASCULAR DISEASE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK FACTOR;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; RISK FACTORS;

EID: 0036615798     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Stamler J, Vacarro O, Neaton JD, Wentworth D, for the Multiple Risk Factor Intervention Trial Research Group. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diab Care 1993;16:434-44.
2. Manson JAE, Colditz GA, Stampfer MJ, et al. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stoke in women. Arch Int Med 1991;151:1141-7.
3. Rastenyte D, Tuomilehto J, Domarkiene S, Cepaitis Z, Reklaitiene R. Risk factors for death from stroke in middle-aged Lithuanian men: results from a 20 year prospective study. Stroke 1996;27:672-6.
4. Haffner SM, Lehto S, Rönnema T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.
5. Reaven GM. Role of insulin resistance in human disease (syndrome X): an expanded definition. Ann Rev Med 1993;44:121-31.
6. Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Int Med 1989;149:1514-20.
7. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-97.
8. World Health Organisation. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1. Diagnosis and classification of diabetes mellitus. Switzerland, Geneva: World Health Organisation; 1999.
9. Möller DE, Flier JS. Insulin resistance, mechanisms, syndromes, and implications. N Engl J Med 1991;325:938-48.
10. Randle PJ. Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. Diabetes Metab Rev 1998;14:263-83.
11. Lewis GF, Steiner G. Acute effects of insulin in the control of VLDL production in humans. Implications for the insulin-resistant state. Diab Care 1996;19:390-3.
12. Reaven GM, Chen YD, Jepessen J, Maheux P, Kraus RM. Insulin resistance and hyperinsulinaemia in individuals with small, dense low-density lipoprotein particles. J Clin Invest 1993;92:141-6.
13. Fontbonne A, Eschwege E. Insulin-resistance, hypertriglyceridaemia and cardiovascular risk: the Paris Prospective Study. Diabet Metab 1991;17:93-5.
14. Bloomfield Rubin H, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. New Engl J Med 1999;341:410-8.
15. Mauvais-Jarvis F, Kahn CR. Understanding the pathogenesis and treatment of insulin resistance and type 2 diabetes mellitus: what can we learn from transgenic and knockout mice? Diabetes Metab 2000;26:433-48.
16. Kuller LH, Velentgas P, Barzilay J, Beauchamp NJ, O'Lear DH, Savage PJ. Diabetes, subclinical cardiovascular disease and risk of incident cardiovascular disease and all-cause mortality. Arterioscler Thromb Vasc Biol 2000;20:823-9.
17. Kuusisto J, Mykkannen L, Pyorala K, Laakso M. Non-insulin-dependent diabetes and its metabolic control are important risk factors of stroke in elderly subjects. Stroke 1994;25:1157-64.
18. Kuusisto J, Mykkannen L, Pyorala K, Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 1994;43:960-7.
19. Hanefeld M, Fischer S, Julius U, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996;39:1577-83.
20. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
21. Stratton IM, Adler AI, Neil HAW, et al., on behalf of the UK Prospective Diabetes Study Group. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000;321:405-12.
22. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.
23. Feskens EJM, Kromhout D. Glucose tolerance and the risk of cardiovascular diseases: the Zutphen Study. J Clin Epidemiol 1992;45:1327-34.
24. Rodriquez BL, Lau N, Burchfield CM, et al. Glucose intolerance and 23-year risk of coronary heart disease and total mortality. Diabetes Care 1996;22:1262-5.
25. Wilson PWF, Cupples LA, Kannel WB. Is hyperglycaemia associated with cardiovascular disease? The Framingham Study. Am Heart J 1991;121:586-90.
26. Fuller JH, Shiplye MJ, Rose G, Jarrett RJ, Keen H. Coronary heart disease risk and impaired glucose intolerance: the Whitehall Study. Lancet 1980;28:1373-6.
27. Fontbonne A, Thibult N, Eschwege E, Ducimetiere P. Body fat distribution and coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes mellitus: The Paris Prospective Study, 15 year follow-up. Diabetologica 1992;35:464-8.
28. Burchfield CM, Curb JD, Rodriquez BL, Abott RD, Chiu D, Yaho K. Glucose intolerance and 22 year stroke incidence: The Honululu Heart Program. Stroke 1994;25:951-7.
29. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diab Care 1999;22:233-40.
30. Barzilay JI, Spiekerman CF, Wahl PW, et al. Cardiovascular disease in older adults with glucose disorders: comparison of American Diabetes Association criteria for diabetes mellitus and WHO criteria. Lancet 1999;354:622-5.
31. Saydah SH, Miret M, Sung J, Varas C, Gause D, Brancati FL. Post-challenge hyperglycaemia and mortality in a national sample of U.S. adults. Diab Care 2001;24:1397-402.
32. The DECODE study group. Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria. Lancet 1999;354:617-21.
33. Shaw JE, Hodge AM, Courten M de, Chitson P, Zimmet PZ. Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality. Diabetologica 1999;42:1050-4.
34. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Funagata Diabetes Study. Diab Care 1999;22:920-4.
35. Yamasaki Y, Kawamori R, Matsushima H, et al. Asymptomatic hyperglycaemia is associated with increased intimal plus medial thickness of the carotid artery. Diabetologica 1995;38:585-91.
36. Hanefeld M, Koehler C, Henkel E, Fuecker K, Schaper F, Temelkova-Kurktschiev T. Post-challenge hyperglycaemia relates more strongly than fasting hyperglycaemia with carotid intima-media thickness: the RIAD Study. Risk Factors in Impaired Glucose Tolerance for Atherosclerosis and Diabetes. Diabet Med 2000;17:835-40.
37. Isomaa B, Almgren P, Foren B, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diab Care 2001;24:683-9.
38. Vegt F de, Dekker JM, Ruhe HG, et al. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologica 1999;42:926-31.
39. Vegt F de, Dekker JM, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ. Similar 9-year mortality risks and reproducibility for the World Health Organization and American Diabetes Association glucose tolerance categories: the Hoorn Study. Diab Care 2000;23:40-4.
40. Khaw KT, Wareham N, Luben R, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of cancer and Nutrition (EPIC-Norfolk). Br Med J 2001;322:1-6.
41. Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000;321:405-12.
42. Wei M, Gibbons LW, Mitchell TL, Kampert JB, Stern MP, Blair SN. Low fasting glucose level as a predictor of cardiovascular disease and all-cause mortality. Circulation 2000;101:2047-52.
43. Ruige JB, Assendelft WJ, Dekker JM, Kostense PJ, Heine RJ, Bouter LM. Insulin and risk of cardiovascular disease: a meta-analysis. Circulation 1998;97:996-1001.
44. Katz RJ, Ratner RE, Cohen RM, Eisenhouwer E, Verme D. Are insulin and pro-insulin independent risk markers for premature coronary artery disease? Diabetes 1996;45:736-41.
45. Dijk RA van, Nijpels G, Twisk JW, et al. Change in common carotid artery diameter, distensibility and compliance in subjects with a recent history of impaired glucose tolerance: a 3-year follow-up study. J Hypertens 2000;18:293-300.
46. Festa A, D'Agostino R Jr, Mykkanen L, Tracy R, Howard BV, Haffner SM. Low-density lipoprotein particle size is inversely related to plasminogen activator inhibitor-1 levels. The Insulin Resistance Atherosclerosis Study. Arterioscler Thromb Vasc Biol 1999;19:605-10.
47. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy, RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102:42-7.
48. Tooke JE. Possible pathophysiological mechanisms for diabetic angiopathy in type 2 diabetes. J Diabetes Complications 2000;14:197-200.
49. Meigs JD, Mittleman MA, Nathan DM, et al. Hyperinsulinaemia, hyperglycaemia, and impaired glucose intolerance, the Framingham offspring study. JAMA 2000;283:221-8.
50. Ai M, Tanaka A, Ogita K, et al. Relationship between hyperinsulinaemia and remnant lipoprotein concentrations in patients with impaired glucose tolerance. J Clin Endocrinol Metab 2000;85:3557-60.
51. Isomaa B, Henricsson M, Almgren P, Tuomi T, Takinen MR, Groop L. The metabolic syndrome influences the risk of chronic complications in patients with type II diabetes. Diabetologia 2001;44:1148-1154.
52. Liao D, Shofer JB, Boyko EJ, et al. Abnormal glucose tolerance and increased risk for cardiovascular disease in Japanese-Americans with normal fasting glucose. Diab Care 2001;24:39-44.
53. Bonora E, Kiechl S, Willeit J, et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 1998;47:1643-9.
54. Stearne MR, Palmer SL, Hammersley MS, et al. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998;317:703-13.
55. Niemeijer-Kanters SDJM, Banga JD, Erkelens DW. Lipid lowering therapy in diabetes mellitus. Neth J Med 2001;58:214-222.
56. Herman WH, Alexander CM, Cook JR, et al. Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes. Findings from the Scandinavian Simvastatin Survival Study. Diab Care 1999;22:1771-8.
57. Vegt F de, Dekker JM, Jager A, et al. Relation of impaired fasting and post-load glucose with incident type 2 diabetes in a Dutch population: The Hoorn Study. JAMA 2001;285:2109-13.
58. Boyko EJ, Courten M de, Zimmet P, Chitson P, Tuomilehto J, Alberti KGMM. Features of the metabolic syndrome predict higher risk of diabetes and impaired glucose intolerance. Diab Care 2000;23:1242-8.
59. Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.
60. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
61. Oldroyd JC, Unwin NC, White M, Imrie K, Mathers JC, Alberti KG. Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diab Res Clin Pract 2001;52:29-43.
62. Erikson KL, Lindgarde F. No excess 12-year mortality in men with impaired glucose tolerance who participated in the Malmo Preventive Trial with diet and exercise. Diabetologia 1998;41:1010-6.
63. Culy CR, Jarvis B. Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus. Drugs 2001;61:1625-60.
64. Parulkar A, Pendergrass ML, Granda-Ayala R, Lee TR, Fonseca VA. Nonhypoglycemic effects of thiazolidines. Ann Int Med 2001;134:61-71.
65. Elasha H, Agrawal A, Jones NP, Bennett SMA, Walker M, Wilding J. Rosiglitazone improves glycaemic and insulinaemic responses in subjects with impaired glucose tolerance. Diabetologia 2001;44(Suppl 1):A221.
66. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus. A randomized controlled trial. JAMA 2000;283:1695-702.
67. Roach P, Yue L, Arora V. Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Diab Care 1999;22:1258-61.
68. Ko GT, Cockram CS, Chan JC. How to minimize missing those subjects with high 2HR plasma glucose but 'normal' fasting plasma glucose levels? J Med 2001;32(1-2):53-65.